These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32735872)

  • 21. D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice.
    Tang DL; Luan YW; Zhou CY; Xiao C
    Acta Pharmacol Sin; 2021 Feb; 42(2):189-198. PubMed ID: 32694753
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine-independent development and maintenance of mouse striatal medium spiny neuron dendritic spines.
    Zhong M; Wang Y; Lin G; Liao FF; Zhou FM
    Neurobiol Dis; 2023 Jun; 181():106096. PubMed ID: 37001611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.
    Espadas I; Darmopil S; Vergaño-Vera E; Ortiz O; Oliva I; Vicario-Abejón C; Martín ED; Moratalla R
    Neurobiol Dis; 2012 Dec; 48(3):271-81. PubMed ID: 22820144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of ghrelin on the motor deficit caused by the ablation of nigrostriatal dopaminergic cells or the inhibition of striatal dopamine receptors.
    Suda Y; Kuzumaki N; Narita M; Hamada Y; Shibasaki M; Tanaka K; Tamura H; Kawamura T; Kondo T; Yamanaka A; Narita M
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1102-1108. PubMed ID: 29378186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CK2 Oppositely Modulates l-DOPA-Induced Dyskinesia via Striatal Projection Neurons Expressing D1 or D2 Receptors.
    Cortés M; Malave L; Castello J; Flajolet M; Cenci MA; Friedman E; Rebholz H
    J Neurosci; 2017 Dec; 37(49):11930-11946. PubMed ID: 29097596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
    Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist.
    Aoyama S; Kase H; Borrelli E
    J Neurosci; 2000 Aug; 20(15):5848-52. PubMed ID: 10908627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P
    Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors.
    Anzalone A; Lizardi-Ortiz JE; Ramos M; De Mei C; Hopf FW; Iaccarino C; Halbout B; Jacobsen J; Kinoshita C; Welter M; Caron MG; Bonci A; Sulzer D; Borrelli E
    J Neurosci; 2012 Jun; 32(26):9023-34. PubMed ID: 22745501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
    Shin E; Lisci C; Tronci E; Fidalgo C; Stancampiano R; Björklund A; Carta M
    Neurobiol Dis; 2014 Feb; 62():233-40. PubMed ID: 24135006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease.
    Rangasamy SB; Dasarathi S; Pahan P; Jana M; Pahan K
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):173-187. PubMed ID: 30187283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice.
    Gomez-Sintes R; Bortolozzi A; Artigas F; Lucas JJ
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1524-33. PubMed ID: 25088904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
    Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
    Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contributions of signaling by dopamine neurons in dorsal striatum to cognitive behaviors corresponding to those observed in Parkinson's disease.
    Darvas M; Henschen CW; Palmiter RD
    Neurobiol Dis; 2014 May; 65():112-23. PubMed ID: 24491966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Jenner P
    Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pitx3 is required for motor activity and for survival of a subset of midbrain dopaminergic neurons.
    van den Munckhof P; Luk KC; Ste-Marie L; Montgomery J; Blanchet PJ; Sadikot AF; Drouin J
    Development; 2003 Jun; 130(11):2535-42. PubMed ID: 12702666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.
    Reavill C; Boyfield I; Coldwell M; Nelson P
    J Pharm Pharmacol; 2000 Sep; 52(9):1129-35. PubMed ID: 11045894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
    Rascol O; Lees AJ; Senard JM; Pirtosek Z; Brefel C; Montastruc JL; Fuell D
    Adv Neurol; 1996; 69():531-4. PubMed ID: 8615176
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.